3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
12
Carcinoma, Hepatocellular
6
Adenocarcinoma
6
Neoplasms
5
Lung Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Breast Neoplasms
4
Urethral Neoplasms
3
Rectal Neoplasms
3
Neoplasm Metastasis
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Ureteral Neoplasms
2
Solid Tumors
2
Sarcoma
2
Non-small Cell Lung Cancer Metastatic
2
Malignant Solid Tumor
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Biliary Tract Neoplasms
2
Thymoma
1
Solid Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Ramucirumab
1
Fluorouracil
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Gastric Adenocarcinoma
×
Ramucirumab
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts